The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1581
September 23, 2019
View Complete Issue         Table of Contents 2019 
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
September 23, 2019 (Issue: 1581)
Lefamulin (Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
Article code: 1581a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.